These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Autocrine transformation of human hematopoietic cells after transfection with an activated granulocyte/macrophage colony stimulating factor gene.
    Author: Hoyle PE, Steelman LS, McCubrey JA.
    Journal: Cytokines Cell Mol Ther; 1997 Sep; 3(3):159-68. PubMed ID: 9426974.
    Abstract:
    The effects of constitutive cytokine gene expression on the growth-factor-dependence of the human erythroleukemic TF-1 cell line have been determined. TF-1 cells normally require the presence of exogenous cytokines to proliferate in vitro. TF-1 cells were transfected with constructs containing either the germline granulocyte-macrophage colony-stimulating factor (GM-CSF) gene or the GM-CSF gene linked to the Moloney murine leukemia virus (Mo-MuLV) long terminal repeat. The Mo-MuLV-LTR, which contains a strong transcriptional enhancer, was added to stimulate the constitutive expression of the GM-CSF gene. Transfection with the germline GM-CSF gene did not abrogate the cytokine dependence of TF-1 cells, indicating that inheritance of an extra copy did not result in sufficient GM-CSF expression to abrogate cytokine dependence. In contrast, transfection with the LTR-modified GM-CSF gene resulted in the isolation of cells that proliferated in the absence of exogenous GM-CSF. The LTR increased nascent transcription and accumulation of GM-CSF mRNA transcripts, which had a normal half-life. This increase in GM-CSF expression led to secretion of sufficient GM-CSF to support the growth of the parental TF-1 cells. These results indicate that the deregulated expression of human cytokine genes induced by certain retroviral LTRs can result in their conversion into hematopoietic-specific oncogenes. These modified human cell lines provide a model to investigate autocrine transformation and therapy of acute myelogenous leukemia as well as other hematopoietic disorders.
    [Abstract] [Full Text] [Related] [New Search]